Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from InMed

INM Stock Alert: What to Know as InMed, Mentari Announce Merger

InMed stock rallied yesterday on a merger announcement with Mentari Therapeutics. Here’s why the transaction is concerning for INM investors.

Barchart · May 20

What's Driving InMed's (INM) 22% After-Hours Surge?

What's Driving InMed's (INM) 22% After-Hours Surge?

InMed Pharmaceuticals Inc. (NASDAQ:INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50.

Benzinga · Nov 20, 2025

InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa

InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa

InMed Pharmaceuticals Inc. (NASDAQ: INM) provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment

Benzinga · Jul 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

InMed Publishes Study On Potential Role Of Rare Cannabinoids For Skin Conditions

InMed Pharmaceuticals Inc. (NASDAQ: INM) announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences.

Benzinga · Jun 14, 2022

InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings

InMed Pharmaceuticals Inc. (NASDAQ: INM) has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08 million of its common shares at a purchase price of $0.858 per share in a registered direct offe

Benzinga · Jun 2, 2022

InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market

Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug development.

Benzinga · May 17, 2022

InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition

InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022.

Benzinga · May 13, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play